![Martin Duvall](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin Duvall
Presidente presso
Oncopeptides, Inc.
Profilo
Martin J.
Duvall is currently the Chairman of Oncopeptides, Inc. and a Director of Oncopeptides Incentive AB. He was previously the Chief Executive Officer & Director of Tocagen, Inc. and the Chief Executive Officer of Oncopeptides AB. He has also held senior positions at Merck & Co., Inc., MGI PHARMA, Inc., ARIAD Pharmaceuticals, Inc., and Abraxis BioScience, Inc. He was a Vice President at Aventis Pharmaceuticals, Inc. Mr. Duvall has a graduate degree from The Johns Hopkins University, an undergraduate degree from Muhlenberg College, and an MBA from the University of Kansas.
Posizioni attive di Martin Duvall
| Società | Posizione | Inizio |
|---|---|---|
MGI PHARMA Biologics, Inc.
 MGI PHARMA Biologics, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical and medical therapies | Corporate Officer/Principal | 01/11/2004 |
Oncopeptides, Inc.
 Oncopeptides, Inc. Medical/Nursing ServicesHealth Services Develops therapies for hematological diseases | Presidente | - |
Oncopeptides Incentive AB | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Martin Duvall
| Società | Posizione | Fine |
|---|---|---|
| ONCOPEPTIDES AB | Amministratore Delegato | 15/11/2021 |
| FORTE BIOSCIENCES, INC. | Amministratore Delegato | 15/06/2020 |
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 26/05/2016 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/09/2011 |
MGI PHARMA, Inc.
 MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology Develops. manufactures & markets pharmaceutical and medical products for therapeutic markets | Corporate Officer/Principal | 27/04/2011 |
Formazione di Martin Duvall
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
69
Relazioni di 1° grado
13
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 13 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology Develops. manufactures & markets pharmaceutical and medical products for therapeutic markets | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Manufactures specialty pharmaceutical products | Health Technology |
Tocagen, Inc.
 Tocagen, Inc. BiotechnologyHealth Technology Develops biopharmaceutical drugs | Health Technology |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Muhlenberg College
 Muhlenberg College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Kansas
 University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oncopeptides AB
 Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
MGI PHARMA Biologics, Inc.
MGI PHARMA Biologics, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical and medical therapies | Health Technology |
Oncopeptides Incentive AB | |
Oncopeptides, Inc.
Oncopeptides, Inc. Medical/Nursing ServicesHealth Services Develops therapies for hematological diseases | Health Services |
